Weight
GLP-2
Metabolic
43
Amino acids
Molecular weight
Peptide
Type
Tirzepatide is a first-in-class dual agonist of the GIP and GLP-1 receptors, approved by the FDA as Mounjaro (type 2 diabetes, 2022) and Zepbound (obesity/weight management, 2023). It suppresses appetite, reduces caloric intake, and improves glycemic control through synergistic incretin signaling. It is used clinically for metabolic disease management and is widely prescribed for significant, sustained weight reduction.
Top researched benefits
SURMOUNT-1 Phase 3 Trial
15mg weekly achieved 22.5% weight loss vs 2.4% placebo over 72 weeks—largest weight loss in pharmaceutical trials.
SURPASS Clinical Program
Superior HbA1c reduction and weight loss compared to insulin, semaglutide, and existing diabetes medications.
Overview of GLP-2
Tirzepatide acts as an agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), selectively engaging cAMP signaling over beta-arrestin recruitment at GLP-1R. This dual receptor activation synergistically enhances insulin secretion, suppresses glucagon, reduces appetite and food intake, and promotes fat mass reduction.
weight loss
- Clinical trials demonstrate 15-22% body weight reduction in non-diabetic obese individuals, superior to existing weight loss medications.
- Improvements in waist circumference, blood pressure, triglycerides, HDL cholesterol, and insulin resistance markers.
- Preferentially reduces visceral adipose tissue while preserving lean muscle mass with resistance training.
diabetes
- Superior HbA1c reduction of 1.5-2.4% in clinical trials.
- Improves insulin sensitivity across diverse populations.
- May help preserve and restore pancreatic beta cell function.
cardiovascular
- 26% reduction in major adverse cardiovascular events demonstrated in SURPASS-CVOT trial.
- Systolic and diastolic blood pressure reductions of 8-12 mmHg.
- Triglyceride improvements of 20-30%, HDL enhancement, and apolipoprotein B reduction.
Typical Dose
2.5mg starting dose, titrated by 2.5mg every 4 weeks to maintenance dose of 5–15mg
Frequency
once weekly subcutaneous injection
Cycle Duration
Start at 2.5mg weekly; increase by 2.5mg every 4 weeks over 20 weeks to reach maximum 15mg maintenance dose
Storage
Unopened: refrigerate at 2–8°C until expiration. Once removed from refrigerator: store below 30°C for up to 21 days. Do not freeze. Compounded lyophilized powder: refrigerate or freeze; once reconstituted, refrigerate at 2–8°C and use within timeframe specified by pharmacy.
Chemical Makeup
Key benefits
Produces up to 20%+ reduction in body weight in adults with obesity, driven primarily by fat mass loss rather than lean mass
Significantly reduces HbA1c by up to 28.2 mmol/mol, improving long-term glycemic control in type 2 diabetes
Reduces energy intake by approximately 500 kcal/day through appetite suppression and reduction in food cravings
Improves cardiovascular and metabolic risk markers including waist circumference, blood pressure, LDL cholesterol, and triglycerides
Community interest
This peptide is still gaining traction in the community.
Dual GIP/GLP-1 Agonist | Diabetes & Weight Loss
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesNoGLP-2 Molecular Information
View the scientifc details of GLP-2.
43
Amino Acids
GLP-2
His
His
Position 1
Sec
Sec
Position 2
Glu
Glu
Position 3
Gly
Gly
Position 4
Thr
Thr
Position 5
Phe
Phe
Position 6
Thr
Thr
Position 7
Ser
Ser
Position 8
Asp
Asp
Position 9
Val
Val
Position 10
Ser
Ser
Position 11
Ser
Ser
Position 12
Tyr
Tyr
Position 13
Leu
Leu
Position 14
Glu
Glu
Position 15
Gly
Gly
Position 16
Gln
Gln
Position 17
Ala
Ala
Position 18
Ala
Ala
Position 19
Lys
Lys
Position 20
Glu
Glu
Position 21
Phe
Phe
Position 22
Ile
Ile
Position 23
Ala
Ala
Position 24
Trp
Trp
Position 25
Leu
Leu
Position 26
Val
Val
Position 27
Arg
Arg
Position 28
Gly
Gly
Position 29
Arg
Arg
Position 30
Gly
Gly
Position 31
Gly
Gly
Position 32
Gly
Gly
Position 33
Gly
Gly
Position 34
Gly
Gly
Position 35
Pro
Pro
Position 36
Ser
Ser
Position 37
Lys
Lys
Position 38
Lys
Lys
Position 39
Lys
Lys
Position 40
Lys
Lys
Position 41
Lys
Lys
Position 42
Lys
Lys
Position 43
Molecular Weight
4813.45DaChain Length
43Amino AcidsType
PeptideGLP-2 Protocols
Subcutaneous injection is the only established and FDA-approved delivery route for tirzepatide (Mounjaro/Zepbound). Preferred injection sites are the abdomen (at least 2 inches from the navel), front outer thigh, or back of the upper arm, rotated weekly to prevent lipohypertrophy.
2.5 mcg
Weight loss — starting dose
Weight loss — starting dose
SubQ
1 week range
5 mcg
Weight loss — first therapeutic dose
Weight loss — first therapeutic dose
SubQ
1 week range
7.5 mcg
Weight loss — intermediate maintenance
Weight loss — intermediate maintenance
SubQ
1 week range
10 mcg
Weight loss — common long-term maintenance
Weight loss — common long-term maintenance
SubQ
1 week range
12.5 mcg
Weight loss — advanced titration
Weight loss — advanced titration
SubQ
1 week range
15 mcg
Weight loss / Type 2 diabetes — maximum dose
Weight loss / Type 2 diabetes — maximum dose
SubQ
1 week range
GLP-2 Reconstitution Guide
Learn how to reconstitute GLP-2
Materials needed
Tirzepatide lyophilized powder vial (e.g., 30mg)
Bacteriostatic water (BAC water), 3mL per 30mg vial
Insulin syringes (0.5–1 mL, 29–31 gauge)
Alcohol swabs
Sharps disposal container
Wash hands thoroughly with soap and water before handling the vial or syringe
Wipe the rubber stopper of the tirzepatide vial and the BAC water vial with separate alcohol swabs and allow to air dry
Draw the calculated volume of bacteriostatic water into an insulin syringe — for a 30mg vial use 3mL BAC water to achieve a 10mg/mL concentration
Insert the needle through the tirzepatide vial stopper at an angle so the tip touches the inside glass wall
Inject the BAC water very slowly, allowing it to trickle down the glass wall — never spray directly onto the lyophilized powder
Remove the syringe and gently swirl the vial in a slow circular motion for 1–5 minutes until the powder fully dissolves into a clear solution — never shake the vial
Label the vial with the date mixed, concentration (e.g., 10mg/mL), and discard date (28–60 days from mixing)
Store reconstituted vial immediately in the refrigerator at 36–46°F (2–8°C) — never freeze
Remove the vial from the refrigerator 15–20 minutes before injecting and allow it to warm to room temperature to reduce injection site discomfort
Draw the calculated dose volume into a fresh insulin syringe — at 10mg/mL, 2.5mg = 0.25mL (25 IU), 5mg = 0.50mL (50 IU), 7.5mg = 0.75mL (75 IU), 10mg = 1.0mL (100 IU)
Clean the chosen injection site with an alcohol swab and allow it to air dry
Pinch the skin at the injection site to elevate subcutaneous fat away from muscle, then insert the needle at 90 degrees (or 45 degrees if very lean)
Slowly depress the plunger, hold the needle in place for 5–10 seconds after the full dose is delivered, then withdraw in one smooth motion
Rotate the injection site each week using a 4-week pattern alternating abdomen sides and thigh sides
GLP-2 Cycle
The GLP-2 Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 16-24
- Peak weight loss effects observed
- Day 1-3
- Appetite reduction begins
- Week 1-2
- Improved blood sugar control (diabetics), mild nausea common
- Week 2-4
- Initial weight loss begins; GI side effects typically improve
- Week 0-0
- 1-3 lbs weight loss per week during active phase
Dosing tools
GLP-2 Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
mg
Enter the total amount of peptide in the vial in milligrams (as stated on the label).
The dose you want to inject per administration, in mcg or mg.
1,000 mcg = 1 mg
1 mL
2 mL
3 mL
5 mL
Custom
Volume of bacteriostatic water you add to reconstitute the powder. Use BAC water for preservation.
Injection Results
Based on your vial and dilution inputs.
GLP-2
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg GLP-2 vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
1mL / 100 units
5 units
0.050 mL
Reference Guide
Dosing Cycle
- Peptide
- GLP-2
- Dosing
- 2.5mg starting dose, titrated by 2.5mg every 4 weeks to maintenance dose of 5–15mg
- Dosing Frequency
- once weekly subcutaneous injection
- Cycle Duration
- Start at 2.5mg weekly; increase by 2.5mg every 4 weeks over 20 weeks to reach maximum 15mg maintenance dose
- Storage
- Unopened: refrigerate at 2–8°C until expiration. Once removed from refrigerator: store below 30°C for up to 21 days. Do not freeze. Compounded lyophilized powder: refrigerate or freeze; once reconstituted, refrigerate at 2–8°C and use within timeframe specified by pharmacy.
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC)contains 0.9% benzyl alcohol for preservation
- Inject water slowlyaim down the vial wall, not directly onto powder
- Never shakegently swirl or roll the vial until dissolved
- Store properlyrefrigerate at 2-8°C after reconstitution
- Use within 28 daysmost reconstituted peptides remain stable for about 4 weeks
- Keep sterilealways clean vial tops with alcohol before drawing
Peptide Interactions
Research suggestions of GLP-2 interactions with other common peptides and substances.
Weight
5am
Longevity
5-Amino-1MQ
COMPATIBLE
NNMT inhibition may complement GLP-1 effects for metabolic optimization.
Healing
bpc
Longevity
BPC-157
COMPATIBLE
No known interactions, may support gut health and reduce GI effects.
Weight
ipa
Growth
Ipamorelin
COMPATIBLE
May help maintain metabolic rate and muscle preservation.
Weight
GLP-1
Metabolic
GLP-1
AVOID
Both are GLP-1 agonists—combining increases hypoglycemia and severe GI side effect risk.
Side effects
Avoid: Do not take GLP-2 with GLP-1.
Contraindications
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy or breastfeeding
History of pancreatitis
Stop signs
Severe/persistent abdominal pain (pancreatitis risk)
Neck lumps, hoarseness, difficulty swallowing (thyroid concerns)
Severe nausea/vomiting preventing adequate nutrition
Severe hypoglycemic signs (confusion, sweating, rapid heartbeat)
Kidney problems (decreased urination, swelling)
Severe allergic reactions (rash, breathing difficulty)
Suicidal thoughts or severe depression
Gallbladder problems (severe upper right pain)
Dehydration from persistent vomiting
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
GLP-2Research References
GLP-2 is a fda approved compound
GLP-2
GLP-2 is a fda approved compound
SURMOUNT-1 Phase 3 Trial
15mg weekly achieved 22.5% weight loss vs 2.4% placebo over 72 weeks—largest weight loss in pharmaceutical trials.
2022
SURPASS Clinical Program
Superior HbA1c reduction and weight loss compared to insulin, semaglutide, and existing diabetes medications.
2021
SURMOUNT-2 T2DM Trial
15mg dose achieved 15.7% weight loss with significant cardiometabolic improvements over 72 weeks.
2023
SURPASS-CVOT Cardiovascular Outcomes
26% reduction in major adverse cardiovascular events, establishing cardioprotective benefits.
2023
Frequently asked questions
What is a peptide dosage calculator?
A peptide dosage calculator is a free tool that converts your vial size, bacteriostatic water volume, and target dose into an exact syringe draw volume. Instead of doing the reconstitution math by hand, you enter three inputs and instantly get the concentration of your solution and how many milliliters or syringeunits to draw. This calculator works for single peptide compounds and multi-peptide blends.
How do I calculate peptide dosage from a vial?
To calculate your peptide dose, divide the total peptide content of your vial in micrograms by the volume of bacteriostatic water you added in milliliters. This gives you your solution concentration in mcg/mL. Then divide your target dose by that concentration to get your draw volume. For example, a 5mg (5,000 mcg) vial reconstituted with 2mL of BAC water gives a concentration of 2,500 mcg/mL. A 250 mcg dose would require drawing 0.1mL. This calculator automates all of those steps instantly.
How much Bacteriostatic water should I add to a peptide vial?
Most people add 2mL to 3mL of bacteriostatic water per vial, but the right amount depends on the dose you want to draw and the syringe size you are using. Adding 1mL to a 5mg vial gives you a concentration of 5,000 mcg/mL, making each dose very small in volume. Adding 2mL gives you 2,500 mcg/mL, which is easier to measure on a standard insulin syringe. A general guideline is to choose a volume that puts your typical dose somewhere between 10 and 30 units on a U-100 syringe. Use the calculator above to test different water volumes and find what works for your dose.
How are peptides different from proteins?
Both are made of amino acids, but peptides are much smaller than proteins. Because of their tiny size, peptides can act like tiny messengers in the body, sending specific signals to your cells to tell them exactly what to do.
Calculate peptide dosages
Learning how to calculate a peptide dose? Use our beginner-friendly peptide dosage, blend, and accumulation calculators. Enter vial size, reconstitution volume, and target dose to get exact draw volumes instantly. No guesswork, just clear guidance that helps prevent common mistakes.
